The strategy belongs to a rapidly growing discipline known as photopharmacology, in which drug molecules are engineered to change their biological activity in response to specific wavelengths of light. The key ingredient in the new study is a class of organic compounds called azobenzenes. Azobenzenes are molecular photoswitches: when exposed to one frequency of light, their central nitrogen-nitrogen double bond flips from a stable, extended trans configuration into a bent cis configuration, and exposure to a different frequency flips them back. Because this transformation is fast, repeatable, and clean, chemists can attach an azobenzene unit to a drug scaffold and effectively give the molecule two distinct shapes, each with its own pharmacological profile.

Trauner’s team used this principle to build a series of morphine-azobenzene hybrids designed to interact with the mu-opioid receptor, the molecular docking site through which morphine, codeine, fentanyl, and most clinical opioids exert their effects. Mu-opioid receptors are G protein-coupled receptors found throughout the brain and spinal cord, on peripheral nerves, and in the gut. When activated, they dampen pain signals with remarkable potency, but because the drugs circulate bodywide, they activate receptors everywhere at once. That indiscriminate activation is what produces the familiar constellation of side effects: constipation as gut motility slows, tolerance as the nervous system adapts, dependence and addiction as reward circuits in the brain are repeatedly engaged, and, most dangerously, suppression of the brainstem signals that control breathing.

Among the compounds the researchers synthesized, one stood out. AM-3 binds and strongly activates the mu-opioid receptor when the azobenzene switch is held in the shape induced by near-ultraviolet light, but binds only weakly when blue light pushes the switch into its alternative configuration. In other words, the same molecule can be a potent opioid or a nearly inactive one, depending entirely on the color of light shining on the tissue. In preclinical pain models, including models of cancer pain, the team showed that illuminating only the region where relief was needed produced substantial analgesia while avoiding tolerance and constipation. Because AM-3 also crosses poorly into the brain, the light-activated drug stays largely out of the central nervous system, minimizing the brain-based hazards of addiction and respiratory depression.

The spatial logic of the approach is what sets it apart from every conventional opioid on the market. A standard painkiller pill distributes its active ingredient through the bloodstream, hitting receptors in the gut, the brainstem, and the reward pathways whether or not they contribute to pain relief. With a photoswitchable opioid, a clinician could in principle illuminate a surgical site, an inflamed joint, or a tumor-adjacent nerve with the activating wavelength and leave the rest of the body in the dark. Receptors outside the illuminated zone would encounter the drug in its weakly active configuration, dramatically narrowing the therapeutic window’s collateral damage. The switch is also fully reversible: shining blue light deactivates the compound, giving practitioners an off switch for opioid activity that no current medication provides.

The achievement is the culmination of two decades of work in Trauner’s laboratory on controlling biology with light. In 2004, Trauner and colleagues at the University of California, Berkeley, demonstrated that a synthetic azobenzene switch could turn the firing of neurons on and off with illumination. That paper appeared months before a landmark study by Karl Deisseroth and colleagues that helped define and establish optogenetics, the technique of using light-sensitive proteins to control nerve cell activity, a field recognized with this year’s Nobel Prize in Physiology or Medicine. Trauner has emphasized that this early history highlights the crucial role chemistry played in the origins of light-based control of the nervous system, a point often overlooked in accounts that focus solely on the genetic engineering side of optogenetics.

Where optogenetics requires introducing light-sensitive proteins into cells genetically, photopharmacology works with ordinary, unmodified tissue. The light-sensitive machinery is the drug itself, which means the approach could in principle be applied without gene therapy. Study co-senior author Joshua Levitz, a professor of biochemistry and biophysics at Weill Cornell Medicine, noted that the idea of light-switchable receptor activators has been around for roughly twenty years, but that these results represent a major step forward. He described the work as significant not just for pain management but for the general strategy of photopharmacology, which he said has a great many potential applications across biology and medicine. The same switching principle could be adapted to other receptor classes and drug families, from anesthetics to cardiovascular medications.

Significant engineering hurdles remain before the technology can reach patients. The activating wavelength for AM-3 lies in the near-ultraviolet range, and ultraviolet light can damage eyes and skin, making it poorly suited for clinical illumination of deep tissue. The teams are already developing successor molecules switchable with safer, longer wavelengths. Trauner said the next step is to make the compounds adaptable for humans, with the goal of shifting their sensitivity toward red light, which penetrates skin and tissue far more deeply than ultraviolet or blue light. He acknowledged that the photochemistry needs improvement but reported that the group has promising ideas and already some exciting preliminary results. Red-shifted switches would allow illumination of internal pain sources through the skin or via minimally invasive optical fibers, opening the door to treating postoperative pain, neuropathic pain, and cancer pain without systemic opioid exposure.

The path forward includes further preclinical development and, ultimately, clinical trials, a process that will need to establish dosing, light-delivery protocols, safety margins, and the practical pharmacology of a drug whose activity depends on an external physical stimulus. The research was supported by the National Institutes of Health and several institutional awards, and several of the investigators, including Levitz and Trauner, are inventors on a provisional patent application covering photoswitchable morphines for pain treatment. Those commercial and translational signals suggest the field is moving beyond proof of concept toward a genuine therapeutic pipeline.

If the approach survives the journey from animal models to human trials, the implications for the opioid crisis could be profound. A painkiller that works only where light is shone, cannot readily reach the brain’s reward and breathing centers, and can be switched off at will would attack the twin epidemics of opioid addiction and overdose at their pharmacological roots rather than through prescribing guidelines alone. For the millions of patients living with severe chronic pain who fear both undertreatment and dependence, a light-activated opioid would represent an entirely new bargain: powerful relief, precisely confined to the site of suffering, with the rest of the body left safely in the dark.

Subject of Research: Photopharmacological development of a light-switchable opioid painkiller targeting the mu-opioid receptor

Article Title: With a flick of a switch: Reducing addiction risk from opioid painkillers

Article References: With a flick of a switch: Reducing addiction risk from opioid painkillers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: photopharmacology, opioids, mu-opioid receptor, azobenzene, photoswitch, pain management, optogenetics, Dirk Trauner, Weill Cornell Medicine, University of Pennsylvania, Cell journal, drug safety